Search

Displaying results 4281 - 4290 of 8575 in total
  1. Drug

    Berahyaluronidase alfa

    go.drugbank.com/drugs/DB22790
    ApprovedInvestigational

    This combination was approved by the US FDA in September 2025 and is indicated for various solid tumors in adults and pediatric patients 12 years and older, offering a subcutaneous option for indications

  2. Drug

    XL784

    go.drugbank.com/drugs/DB04991
    Investigational

    Results of single dose Phase I clinical trials of XL784 administered orally to 96 healthy volunteers have demonstrated that XL784 has attractive safety and pharmacokinetic profiles. … XL784 was specifically optimized to be MMP-1 sparing, thus potentially enhancing its safety profile and enabling higher dosing compared with other previously studied metalloprotease inhibitors.

  3. Drug

    BMS-986141

    go.drugbank.com/drugs/DB14942
    Investigational

    BMS-986141 is under investigation in clinical trial NCT02985632 (A Study to Evaluate the Pharmacokinetics of BMS-986141 in Participants With Hepatic Impairment Compared to Healthy Participants).

  4. Drug

    Bucindolol

    go.drugbank.com/drugs/DB12752
    Investigational

    Bucindolol has been investigated in Heart Failure.

  5. Drug

    Tivantinib

    go.drugbank.com/drugs/DB12200
    Investigational

    Tivantinib has been investigated in Solid Tumors.

  6. Drug

    5-amino-1,3,4-thiadiazole-2-thiol

    go.drugbank.com/drugs/DB12348
    Investigational

    ATT has been investigated in Pulmonary Tuberculosis.

  7. Drug

    Ilaprazole

    go.drugbank.com/drugs/DB11964
    Investigational

    Ilaprazole has been investigated in Helicobacter Infections.

  8. Drug

    Caprylic acid

    go.drugbank.com/drugs/DB04519
    ApprovedInvestigationalWithdrawn

    Caprylic acid is an eight-carbon chain fatty acid, also known systematically as octanoic acid. It is found naturally in coconuts and breast milk.

  9. Drug

    Physostigmine

    go.drugbank.com/drugs/DB00981
    Approved

    It also can cross the blood-brain barrier and is used when central nervous system effects are desired, as in the treatment of severe anticholinergic toxicity.

  10. Drug

    Padeliporfin

    go.drugbank.com/drugs/DB15575
    ApprovedInvestigational

    [A244699] Padeliporfin was first approved by the European Commission on November 10, 2017, for the treatment of low-risk prostate cancer in adults meeting certain clinical criteria.[L39799]